Boothbay Fund Management’s Cidara Therapeutics CDTX Stock Holding History

Boothbay Fund Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-82,500	Closed	-$18.2M	–	2103
2025 Q4	$18.2M	Buy	+82,500	New	+$13.3M	0.27%	53
2025 Q3	–	Sell	-181,200	Closed	-$8.83M	–	1891
2025 Q2	$8.83M	Buy	+181,200	New	+$4.35M	0.17%	155

Boothbay Fund Management's CDTX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 79,587 shares — an estimated $17.6M sold.

Boothbay Fund Management first reported a position in CDTX in Q2 2017 and held it in 14 quarters. The position peaked at $17.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Boothbay Fund Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Boothbay Fund Management sold 79,587 Cidara Therapeutics shares in Q1 2026, an estimated $17.6M.
Boothbay Fund Management first reported a position in Cidara Therapeutics in Q2 2017 and held it in 14 quarters.
Boothbay Fund Management's Cidara Therapeutics position peaked at $17.6M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.